← Back to Screener
Cel-Sci Corporation (CVM)
Price$4.64
Favorite Metrics
Price vs S&P 500 (26W)-60.32%
Price vs S&P 500 (4W)16.18%
Market Capitalization$38.82M
All Metrics
Book Value / Share (Quarterly)$1.32
P/TBV (Annual)4.64x
Cash Flow / Share (Quarterly)$-2.02
Price vs S&P 500 (YTD)-19.37%
Net Profit Margin (TTM)-5445.76%
EPS (TTM)$-5.24
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-5.24
EPS (Annual)$-21.72
ROI (Annual)-129.11%
Net Profit Margin (5Y Avg)-8345.71%
Cash / Share (Quarterly)$0.75
ROA (Last FY)-105.46%
EBITD / Share (TTM)$-3.51
ROE (5Y Avg)-201.32%
Operating Margin (TTM)-5218.40%
Cash Flow / Share (Annual)$-2.14
P/B Ratio3.49x
P/B Ratio (Quarterly)3.97x
EV / Revenue (TTM)71.52x
Net Interest Coverage (TTM)-46.67x
ROA (TTM)-102.18%
EPS Incl Extra (Annual)$-21.72
Current Ratio (Annual)2.26x
Quick Ratio (Quarterly)1.25x
3-Month Avg Trading Volume0.06M
52-Week Price Return-39.17%
Tangible BV / Share (Quarterly)$1.31
P/S Ratio (Annual)69.49x
Asset Turnover (Annual)0.01x
52-Week High$13.48
Operating Margin (5Y Avg)-10456.68%
EPS Excl Extra (Annual)$-21.72
CapEx CAGR (5Y)-57.33%
Tangible BV CAGR (5Y)-3.99%
26-Week Price Return-56.33%
Quick Ratio (Annual)2.14x
13-Week Price Return-14.62%
Total Debt / Equity (Annual)0.50x
Current Ratio (Quarterly)1.39x
Enterprise Value$39.957
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)31.34%
Pretax Margin (Annual)-5415.68%
Cash / Share (Annual)$1.37
3-Month Return Std Dev98.43%
ROE (Last FY)-243.62%
Net Interest Coverage (Annual)-41.02x
EPS Basic Excl Extra (Annual)$-21.72
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.67x
EPS Incl Extra (TTM)$-5.24
Receivables Turnover (Annual)0.00x
ROI (TTM)-127.05%
P/S Ratio (TTM)69.49x
Pretax Margin (5Y Avg)-8345.71%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.98
Price vs S&P 500 (52W)-69.00%
Year-to-Date Return-16.73%
5-Day Price Return2.34%
EPS Normalized (Annual)$-21.72
ROA (5Y Avg)-76.16%
Net Profit Margin (Annual)-5415.68%
Month-to-Date Return36.45%
Cash Flow / Share (TTM)$-0.67
EBITD / Share (Annual)$-18.59
Operating Margin (Annual)-5188.32%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-94.73%
LT Debt / Equity (Quarterly)0.10x
EPS Basic Excl Extra (TTM)$-5.24
P/TBV (Quarterly)4.01x
P/B Ratio (Annual)4.61x
Pretax Margin (TTM)-5445.76%
Book Value / Share (Annual)$1.99
Price vs S&P 500 (13W)-15.31%
Beta1.03x
Revenue / Share (TTM)$0.00
ROE (TTM)-226.10%
52-Week Low$1.98
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CVMCel-Sci Corporation | 69.49x | — | — | — | $4.64 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
CEL-SCI Corp is a late-stage biotechnology company developing immunotherapies designed to leverage the immune system against cancer and autoimmune diseases. Its lead program, Multikine, is in Phase 3 clinical trials for head and neck cancer. The company is also advancing its LEAPS technology platform for potential treatment of rheumatoid arthritis.